United Therapeutics (NASDAQ:UTHR) Posts Quarterly Earnings Results, Misses Expectations By $0.30 EPS

Key Points

• United Therapeutics reported Q3 EPS of $5.71, missing estimates by $0.30 and down from $7.16 a year earlier. Revenue rose 4.1% year over year to $832.5 million, topping analyst expectations.
• Management highlighted record quarterly revenue, including $504 million from Tyvaso, citing sustained demand and stronger commercial execution.
• The planned soft-mist inhaler NDA filing was delayed from year-end 2026 to 2027 after FDA discussions called for more supporting data; ralinepag also faces potential regulatory or supply risk tied to its API supplier.

United Therapeutics (NASDAQ:UTHR - Get Free Report) posted its quarterly earnings results on Wednesday. The biotechnology company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.01 by ($0.30), FiscalAI reports. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $832.50 million during the quarter, compared to analysts' expectations of $781.14 million. During the same quarter last year, the firm earned $7.16 EPS. The firm's quarterly revenue was up 4.1% compared to the same quarter last year.

Here are the key takeaways from United Therapeutics' conference call:

• United Therapeutics reported record third-quarter revenue of $833 million, including record Tyvaso revenue of $504 million. Management attributed growth to sustained demand, stronger commercial execution, higher dosing and expanded field-force reach; October referrals also reached a monthly record.
• A court decision upholding the company’s intellectual property and a settlement with Liquidia remove PH-ILD from YUTREPIA’s label and bar its promotion for that indication. Management expects limited near-term patient switching, while emphasizing new prescriptions and market expansion as the main Tyvaso growth opportunity.
• The planned soft mist inhaler NDA filing has been pushed from year-end 2026 to 2027 after FDA discussions identified a need for additional supporting data, delaying a potential product opportunity.
• Ralinepag’s FDA application remains under review with a June 24, 2027 PDUFA date, but its API supplier has an Official Action Indicated compliance status. The company is pursuing remediation and says it has contingency plans, though the issue could pose a regulatory or supply risk.
• The FDA indicated that bioequivalence data would not be sufficient to support filing the triple oral pill; the company is evaluating alternative development and filing approaches, with no timeline disclosed.

United Therapeutics Trading Up 1.3%

Shares of UTHR traded up $7.66 during midday trading on Wednesday, reaching $608.98. 677,575 shares of the company were exchanged, compared to its average volume of 555,766. The stock has a 50-day moving average price of $530.53 and a 200-day moving average price of $531.77. The company has a market cap of $26.12 billion, a price-to-earnings ratio of 21.79, a P/E/G ratio of 4.32 and a beta of 0.49. United Therapeutics has a 1-year low of $432.53 and a 1-year high of $614.23.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: BTIG Research raised its price target to $768 from $728 and reiterated a Buy rating, signaling continued upside expectations. BTIG Research rating
• Positive Sentiment: Q3 revenue rose 4.1% year over year to $832.5 million, beating analysts’ expectations of about $781 million. Management also described the company as entering a period of significant growth. Third-quarter financial results
• Neutral Sentiment: United Therapeutics announced a buyout of Pfizer royalties linked to ralinepag, a lung-disease therapy. The move could improve UTHR’s share of future economics, but the supplied report does not detail the transaction’s cost or financial impact. Ralinepag royalty buyout
• Negative Sentiment: Q3 EPS of $5.71 missed analyst expectations and declined from $7.16 a year earlier; reports also said net income fell. This earnings shortfall tempers the stronger revenue result. Q3 earnings miss
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares, about 2.84% of her reported position. She retained 324,443 shares after the sale, which may moderate concern about the transaction. SEC insider-sale filing

United Therapeutics declared that its board has approved a stock repurchase plan on Thursday, October 22nd that authorizes the company to buy back $2 billion in shares. This repurchase authorization authorizes the biotechnology company to purchase up to 8.3% of its shares through open market purchases. Share repurchase plans are usually an indication that the company's leadership believes its shares are undervalued.

Analyst Ratings Changes

Several analysts have recently issued reports on UTHR shares. BTIG Research boosted their price objective on shares of United Therapeutics from $728.00 to $768.00 and gave the company a "buy" rating in a research note on Wednesday. Raymond James Financial set a $720.00 price objective on United Therapeutics in a report on Wednesday. UBS Group set a $725.00 target price on United Therapeutics in a research report on Monday, October 19th. Morgan Stanley lifted their target price on United Therapeutics from $515.00 to $566.00 and gave the company an "equal weight" rating in a report on Wednesday, October 7th. Finally, Bank of America lowered their price target on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a research report on Friday, July 10th. Thirteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, United Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $674.00.

Insider Transactions at United Therapeutics

In related news, EVP Paul Mahon sold 8,300 shares of the firm's stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $544.30, for a total transaction of $4,517,690.00. Following the sale, the executive vice president directly owned 45,172 shares in the company, valued at approximately $24,587,119.60. This trade represents a 15.52% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Martine Rothblatt sold 9,500 shares of the business's stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $596.22, for a total value of $5,664,090.00. Following the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at $193,439,405.46. This trade represents a 2.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 401,528 shares of company stock valued at $211,631,836. Insiders own 8.60% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company's portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.